VCYT Stock Overview
Operates as a diagnostics company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Veracyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.97 |
| 52 Week High | US$30.86 |
| 52 Week Low | US$18.61 |
| Beta | 1.64 |
| 11 Month Change | 39.33% |
| 3 Month Change | 40.24% |
| 1 Year Change | 19.17% |
| 33 Year Change | -26.09% |
| 5 Year Change | 16.89% |
| Change since IPO | 126.19% |
Recent News & Updates
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Jul 02Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Recent updates
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Jul 02Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Shareholder Returns
| VCYT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 38.8% | -2.2% | -2.3% |
| 1Y | 19.2% | 13.9% | 16.7% |
Return vs Industry: VCYT exceeded the US Biotechs industry which returned 11.5% over the past year.
Return vs Market: VCYT exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| VCYT volatility | |
|---|---|
| VCYT Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VCYT's share price has been volatile over the past 3 months.
Volatility Over Time: VCYT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 815 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
Veracyte, Inc. Fundamentals Summary
| VCYT fundamental statistics | |
|---|---|
| Market cap | US$2.29b |
| Earnings (TTM) | -US$54.04m |
| Revenue (TTM) | US$399.58m |
5.7x
P/S Ratio-42.4x
P/E RatioIs VCYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCYT income statement (TTM) | |
|---|---|
| Revenue | US$399.58m |
| Cost of Revenue | US$122.07m |
| Gross Profit | US$277.51m |
| Other Expenses | US$331.55m |
| Earnings | -US$54.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 69.45% |
| Net Profit Margin | -13.52% |
| Debt/Equity Ratio | 0% |
How did VCYT perform over the long term?
See historical performance and comparison